Clinical Trials

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

Phase 2 Recruiting

185 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02938442 2024-11-07

Vaccination of Triple Negative Breast Cancer Patients

Phase 1/2 Completed

16 enrolled 30 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Phase 2 Not yet recruiting

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

17 enrolled 8 charts

Phase 2/3 Active not recruiting

Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

9 enrolled 17 charts

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Phase 2 Unknown

82 enrolled

Triple Negative Breast Neoplasms

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2 Terminated

8 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

83 enrolled

Triple Negative Breast Neoplasms

NCT03634150 2021-10-26

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Phase 1/2 Withdrawn

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Phase 2 Unknown

30 enrolled

Triple Negative Breast Neoplasms

NCT02833766 2021-09-29

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

Phase 2 Terminated

48 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02413320 2021-05-10

NeoSTOP

101 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02032277 2021-01-20

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3 Completed

634 enrolled

Neoplasms, Triple Negative Breast Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

60 enrolled 26 charts

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

522 enrolled

Triple Negative Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

45 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02637375 2016-05-30

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Phase NA Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Phase 2 Unknown

164 enrolled

Triple Negative Breast Neoplasms

NCT01672671 2015-11-03

BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

41 enrolled

Triple Negative Breast Neoplasms

NCT01969032 2014-11-05

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer

41 enrolled

Triple Negative Breast Neoplasms

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Withdrawn